Our research group is aimed at improving patients’ quality of life and bettering their treatment by developing innovative medical technologies.

Specifically, we will focus on targeting metastatic cancer with nanotechnology, and on constructing miniature medical devices that couple diagnosis to therapy (theranostic devices).

Patient-specific biomarkers have helped to advance personalized medicine, however, much remains unknown when predicting whether a certain patient will or will not respond to therapy. In our lab, a nanoparticle-based technology for predicting the therapeutic potency of drugs is developed. Once a tumor is detected, a cocktail of DNA-barcoded nanoparticles, each containing a different drug, is injected intravenously. The particles accumulate in the various cells that compose the tumor microenvironment, utilizing the enhanced permeability and retention (EPR) effect.